Etanercept;Etanercept

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 11 I, 2005, Pages 861-876

  Sparsa, A ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB;

ANKYLOSING SPONDYLITIS; ARTICLE; DISEASE SEVERITY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HUMAN; PRESCRIPTION; PSORIASIS; RHEUMATOID ARTHRITIS; THERAPY EFFECT; TREATMENT CONTRAINDICATION;

EID: 29844451950     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(05)79505-3     Document Type: Article

References (153)

1. Nawroth PP, Bank I, Handley D, Casimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986;163:1363-75.
2. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF-δ antibodies on synovial cell interleukin 1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
3. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell culture. Comparison of monoclonal anti-TNF δ antibody with the interleukine-1 recepteur antagonist. Eur Cytokine New 1995;6:225-30.
4. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony stimulating factor in rheumatoid arthritis regulation by tumor necrosis factor-δ. Eur J Immunol 1991;21:2575-9.
5. Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS. Highly increased levels of tumor necrosis factor-δ and other proinflammatory cytokines in psoriasic arthritis synovial fluid. J Rheumatol 1997;24:518-23.
6. Husby G, Williams RC Jr. Synovial localization of tumor necrosis factor in patient with rheumatoid arthritis. J Autoimmun 1988;1:363-71.
7. Saklatvala J. Tumor necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-9.
8. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 1986;319:516-8.
9. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
10. Joosten LAB, Helsen MMA, Van De Loo FAJ, Paul LC. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1mice. Arthritis Rheum 1996;39:797-809.
11. Saxne T, Palladino MA, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
12. Choy EHS, Panayi GS. Cytokine pathway and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
13. Deleuran BW, Chu C-Q, Field M, Brennan FM, Mitchell T, Feldmann M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992;35:1170-8.
14. Choy EHS, Panayi GS. Cytokine pathway and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
15. Heilig B, Wermann M, Gallati H, Brockhaus M, Berke B, Egen O, et al. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin Invest 1992;70:22-7.
16. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF alpha, IL-1 beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997;14:145-53.
17. Lontz W, Sirsjo A, Liu W, Lindberg M, Rollman O, Torma H. Increased Mrna expression of manganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-1 beta and TNF alpha. Free Radic Biol Med 1995;18:349-55.
18. Kaluza W, Reuss E, Grossmann S, Hug R, Schopf RE, Galle PR, et al. Different transcriptional activity and in vitro TNF alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 2000;114:1180-3.
19. Bonifati C, Carducci M, Cordiali FP, Viola M, Tomaselli R, Sacerdoti G, et al. Correlated increases of tumor necrosis factor alpha, interleukine 6 and granulocyte monocyte colony stimulating factor levels succion blister fluid and sera of psoriatic patients-Relationship with disease severity. Clin Exp Dermatol 1994;19:383-7.
20. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor alpha (TNF-Alpha) biological activity in psoriatic skin lesion. Clin Exp Immunol 1994;96:146-1.
21. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, et al. Serum TNF alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regulat Homeostat Agents 1997;11:115-8.
22. Nickoloff BJ, Karabin GD, Barker JN, Griffiths CE, Sarma V, Mitra RS, et al. Cellular localization of interleukin 8 and its inducers, tumor necrosis factor alpha in psoriasis. Am J Pathol 1991;138:129-40.
23. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999;38:241-51.
24. Poltorak A, Peppel K, Beutler B. Receptor mediated label transfer assay (RELAY): a novel method for the detection of plasma tumor necrosis factor at molar concentration. J Immunol Meth 1994;169:93-9.
25. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneous as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
26. Barone D, Krantz C, Lambert D, Maggiora K, Mohler K. Comparative analysis of the ability of etanercept and inflaximab to lyse TNF-expressing cells in a complement dependent fashion. Arthritis Rheum 1999;42 (Suppl.):S90.
27. Drynda S, Kühne C, Kekow J. Soluble tumor necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Ann Rheum Dis 2002;61:254-6.
28. Catrina AI, Lampa J, Ernestam S, Klint E, Bratt J, Klareskog L, et al. Anti-tumor necrosis factor (TNF) alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP-3) and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 2002;41:484-9.
29. Verschueren PC, Markusse H, Smeets TJM, Kraan MC, Breedveld FC, Tak PP. Reduced cellularity and expression of adhesion molecules and cytokines after treatment with soluble human recombinant TNF receptor (P75) in RA patients. Arthritis Rheum 1999;42 (Suppl):S197.
30. Schottr H, Willeke P, Schorat MA. Long term treatment with etanercept significantly reduces the number of TNF alpha and IL-1 producing peripheral blood mononuclear cells from patients with rheumatoid arthritis. Arthritis Rheum 2001;44(Suppl):S115.
31. Lampa J, Berg L, Rogberg S. Functional effects on peripheral T-cells of treatment with soluble TNF alpha receptor in rheumatoid arthritis. Ann Rheum Dis 2000;59(Suppl 1):163.
32. Jarvis B, Faulds D. Etanercept. A review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
33. Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol 2005;32(Suppl 74):13-8.
34. Alldred A. Etanercept in rheumatoid arthritis. Expert Opin Pharmacother 2001;2:1137-48.
35. Nestorov IP, Devries TP, Zitnik RM. Comparative pharmacokinetics of etanercept in patients with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2004;50 (Suppl 3):S572.
36. Mentions Légales. Résumé Caractéristiques Produits. Dictionnaire Vidal 2005.
37. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;17:337:141-7.
38. Wajdula J. On Behalf of the Etanercept European Investigators Networks. A double-blind, placebo-controlled study of the efficacy and safety of four different doses of etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2000;59(Suppl 1):S163.
39. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Kleischman RM, Fox IR, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patient with rheumatoid arthritis receiving Methotrexate. N Engl J Med 1999;340:253-9.
40. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
41. Willis RF, Pedersen R. Etanercept European Investigators Network. A long term, open-label trial of the safety and efficacity of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis. J Rheumatol 2001;28 (Suppl63):101.
42. Klareskog L, Wajdula J, Pedersen R. A long-term, open-label trial of the safety and efficacity of etanercept (25mg twice weekly) in patients with rheumatoid arthritis. Ann Rheum Dis 2002;61(Suppl 1):175.
43. Moreland LW, Cohen SB, Fleischmann RM. Safety and efficacy of up to 5 years of etanercept (Enbrel®) therapy in rheumatoid arthritis. Ann Rheum Dis 2002;61(Suppl 1):183.
44. Weinblatt ME, Kremer JM, Lange MI. Long term safety and efficacity ofombination therapy with méthotrexate and etanercept (Enbrel®). Arthritis Rheum 1999;42(Suppl 9):40.
45. Kremer JM, Weinblatt ME, Fleischmann RM. Etanercept (Enbrel®) in addition to methotrexate in rheumatoid arthritis long term observation. Arthritis Rheum 2001;44(Suppl 9):78.
46. Kremer JM, Weinblatt ME, Fleischmann RM. Etanercept (Enbrel®) in addition to methotrexate in rheumatoid arthritis long term observation. Ann Rheum Dis 2002;61(Suppl 1):181.
47. Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Vanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000;22:128-39.
48. Yelin E, Roepke L, Katz P. Long-term impact of Enbrel on functional status of persons with RA. Arthritis Rheum 2000;43(Suppl 9):147.
49. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EJ, et al. A comparison of etanercept and méthotrexate in patients with early rheumatoid arthritis. N Engl J Med 2001;343:1586-93.
50. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus méthotrexate in patients with early rheumatoid arthritis. Two years radiogaphics and clinical outcome. Arthritis Rheum 2002;46:1443-50.
51. Genovese M, Martin R, Fleischmann R. Etanercept in early erosive rheumatoid arthritis (ERA trial): observations at 3 years. Arthritis Rheum 2001;44(Suppl):78.
52. Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. A randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
53. Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-62.
54. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
55. Lovell DJ, Giannini EH, reiff A, Jones OY, Schneider R, Olson JC, et al. Long term efficacy and safety of etanercept in children with polyarticular-course juvenile an ongoing multicenter, open label, extended treatment trial. Arthritis Rheum 2003;48:218-26.
56. Oh CJ, Das KM, Gottlieb AB. Treatment with tumor necrosis factor alpha monoclonal antibody dramatically decreases the clinical activity of psoriasis lesion. J Am Acad Dermatol 2000;42:829-30.
57. Mease JP, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJI. Etanercept in the treatment of psoriasis arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
58. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Oru P, et al. Etanercept treatment of psoriatic arthritis. Arthritis Rheum 2004;50:2264-72.
59. Mease P. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin Exp Rheumatol 2002;20 (Suppl. 28):S116-21.
60. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
61. Papp KA, Tyring S, Lahfa M, Pring J, Griffiths CEM, Nakanishi AM, et al. A global phase III randomized trial of etanercept in psoriasis: afety, efficacy and effect of dose reduction. Br J Dermatol 2005;152:1304-12.
62. Prahalad S, Bove KE. Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001;28:2120-4.
63. Arostegui JI, Solis P, Aldea A, Cantero T, Rius J, Bahillo P, et al. Etanercept plus methotrexate treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr 2005;164:13-6.
64. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003;48:2645-51.
65. Federico G, Rigante D, Pugliese AL, Ranno O, Catania S, Stabile A. Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol 2003;32:312-4.
66. Khanna D, Liebling MR, Louis JS. Etanercept ameliorates sarcoïdosis arthritis and skin disease. J Rheumatol 2003;30:1864-7.
67. Utz JP, Limper AH, Kafra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-85.
68. Pasternack FR, Fox LP, Engler DE. Silicone gralunomas treated with etanercept. Arch Dermatol 2005;141:13-5.
69. Mc Gowan JW, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 2004;3:441-4.
70. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO. Generalised pustular psoriasis induced by cyclosporine. A withdrawal responding to tumor necrosis factor alpha inhibitor etanercept. Dermatology 2002;205:213-6.
71. Stone JH, Uhlfelder ML, Hellman DB, Crook S, Bedoes NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis : a six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149-54.
72. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol 2004;51:200-4.
73. Tucuncu Z, Morgan GJ Jr, Kavanaugh A. Anti-TNF therapy for other inflammatory. Clin Exp Rheumatol 2002; 20 (Suppl 28):S146-51.
74. Sacher C, Rubbert A, Konig C, Scherffetter-Kochanek K, Krieg T, Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002;46:113-5.
75. Strober BE, Siu K, Alexis AE, Kim G, Washenik K, Sinha A, et al. Etanercept does not effectively treat moderate to severe alopecia areata : an open-label study. J Am Acad Dermatol 2005;52:1082-4.
76. Day R. Adverse reactions to TNF alpha inhibitors in rheumatoid arthritis. Lancet 2002;359:540-1.
77. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 2004;15:280-94.
78. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchin C, Gaspari AA. A recombinant tumor necrosis factor alpha receptor : Fc fusion protein. Clinical, histological and immunophenotypic characteristics of injection site reactions associated with etanercept. Arch Dermatol 2001;137:893-9.
79. Galaria NA, Werth VP, Schumacher HR. Leukocytoclasic vasculitis due to etanercept. J Rheumatol 2000;27:2041-4.
80. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002;41:116-7.
81. Roux CH, Brocq O, Breuil VAC, Euller-Ziegler L. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. J Joint Bone Spine 2004;71:444-5.
82. Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel J et al. Leukocytoclastic vasculitis associated with tumor necrosis factor alpha blocking agents. J Rheumatol 2004;31:1955-8.
83. Misery L, Perrot JL, Gentil-Perret A, Pallot-Prades B, Cambazard F, Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002;146:334-5.
84. Kekow J, Weite T, Kellner U, Pap T. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept. Arthritis Rheum 2002;46:843-4.
85. Mangge H, Gindl S, Kenzian H, Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor alpha therapy. J Rheumatol 2003;30:2506-7.
86. Soliotis F, Jawad ASM, Glover M. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis 2002;61:850-1.
87. Skytta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000;18:533-4.
88. Hashkes PJ, Shajrawi I. Sarcoid-related uveitis méthotrex during etanercept therapy. Clin Exp Rheumatol 2003;21:645-6.
89. Klareskog L, Moreland LM, Bohen SB. Global safety and efficacy of up to five years of etanercept (Enbrel®) therapy. Arthritis Rheum 2001;44 (Suppl 9):S77.
90. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:573-5.
91. Sabath DF, Holman J, Wallis WJ. Serious infection reports with etanercept. Ann Rheum Dis 2002;61 (Suppl 1):38.
92. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996;334:1697-702.
93. Aboulafia DM, Bundow D, Wilske K, Ochs UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000;75:1093-8.
94. Slifman NR, Gershon S, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infections as a complication of treatment with tumor necrosis factor alpha neutralising agents. Arthritis Rheum 2003;48:319-24.
95. Smith D, Letendre S. Viral pneumonia as a serious complication of etanercept therapy. Ann Intern Med 2002;136:174.
96. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatning histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonist infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
97. Gonzalez-Vicent M, Diaz MA, Sevilla J, Madero L. Cerebral toxoplasmosis following etanercept treatment for idiopathic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation. Ann Hematol 2003;82:649-53.
98. Gottlieb GS, Lesser CF, Holmes KK, Wald A. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor alpha antagonist. Clin Infect Dis 2003;37:838-40.
99. Lassoued S, Sire S, Farny M. Pulmonary aspergillosis in a patient with rheumatoid arthritis treated by etanercept. Clin Exp Rheumatol 2004;22:267-8.
100. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious disease associated with tumor necrosis factor antagonist. Clin Inf Dis 2004;38:1261-5.
101. Pham T, Claudepierre P, Deprez X, Fautrel B, Goupille P, Hilliquin P, et al. Anti-TNF alpha therapy and safety monitoring. Joint Bone Spine 2005;72 (Suppl 1):S1-60.
102. Derk CT, De Horatius RJ. Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis 2003;62:372.
103. Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol 2003;21:526.
104. Kaplan G, Freedman VH. The role of cytokine in the immune response to tuberculosis. Res Immunol 1996;147:565-72.
105. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
106. Yim K, Nazeer SH, Kiska D, Rose FB, Brown D, Cynamon MH. Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. Scand J Infect Dis 2004;36:150-3.
107. Van Oosten BW, Barkhof F, Truyen, Lorniga JB, Bertelsmann FW, Von Blomberg BME, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody Ca2. Neurology 1996;47:1531-4.
108. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-8.
109. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelinisation occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheumn 2001;44:2862-9.
110. Van Der Laken CJ, Lems WF, Van Soesbergen RM, Van Der Sande JJ, Dijmans BAC. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum 2003;48:269-70.
111. Brion PH, Mittal-Henkle A, Kalunian KG. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999;131:634.
112. Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol 2000;12:49-52.
113. Bleumink GS, Ter Borg EJ, Ramselaar CG. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001;40:1317-9.
114. Carlson E, Rothfield N. Etanercept-induced lupus like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 2003;48:1165-6.
115. Cainrs AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002;61:1031-2.
116. Lepore L, Marchetti F, Facchini SL. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheum 2003;21:276-7.
117. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MHA. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003;28: 604-7.
118. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus with etanercept therapy. Lancet 2002;359:579-80.
119. Ferraccioli GF, Assaloni R, Perin A. Drug-induced systemic lupus erythematosus and TNF alpha blockers. Lancet 2002;360:645.
120. De Bandt M, Sibila J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a french national survey. Arthritis Res Therapy 2005;7: R545-51.
121. Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al Saab S, et al. Aplastic anemia following administration of a tumor necrosis factor alpha inhibitor. Eur J Haematol 2003;71:396-8.
122. Backland G, Nossent H. Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford) 2003;42:900-1.
123. Ekstrom K, Hjalgrim H, Brandt L, Backlund E, Klareskog L, Ekbom A, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963-70.
124. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9.
125. Mellemkjaer L, Linet MS, Gridley G. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
126. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patient with rheumatoid arthritis : nested case control study. Br Med J 1998;317:180-1.
127. Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 2001;15:1101-8.
128. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
129. Sabath DF, Wallis WJ, Burge DJ. Lymphoma reports with etanercept (Enbrel) therapy. Ann Rheum Dis 2002;61:182.
130. Askling J, Klareskog L, Hjalgrim H, Baecklund E, Björkholm M, Ekbom A. Do steroids increase lymphoma risk? A case control study of lymphoma risk in polymyalgia rheumatica/ giant cell arteritis. Ann Rheum Dis 2005:[Epub ahead of print].
131. The Wegener's granulomatosis etanercept trial (WGET) Research Group. Etanercept plus standard therapy for Wegener' granulomatosis. N Engl J Med 2005;352:351-61.
132. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001;45:953-6.
133. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor alpha are resistant to skin carcinogenesis. Nat Med 1999;5:828-31.
134. Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 2005;141:861-4.
135. Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest 2002;122:1858-60.
136. Andres E, Limbach FX, Goichot B, Sibilia J. Silent thyroiditis associated with etanercept in rheumatoid arthritis. Ann Rheum Dis 2002;61:565.
137. Allanore Y, Bremont C, Kahan A, Menkes CJ. Transient hyperthyroidism in a patient with rheumatoid arthritis treated by etanercept. Clin Exp Rheumatol 2001;19:356-7.
138. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case report of heart failure after therapy with tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
139. Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. Psoriatic lesions induced by antitumour necrosis factor alpha treatment: two cases. Br J Dermatol 2004;150:506-7.
140. Creaven PJ, Stoll HL Jr. Response to tumor necrosis factor in two cases of psoriasis. J Am Acad Dermatol 1991;24:735-7.
141. Takematsu H, Ozawa H, Yoshimura T. Systemic TNF administration in psoriatic patients: a promising therapeutic modality in severe psoriasis. Br J Dermatol 1991;124:209-10.
142. Elwood RL, Pelszynski MM, Corman LI. Multifocal septic arthritis and osteomyelitis caused by group A streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J 2003;22: 286-8.
143. Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arhtritis Rheum 2000;43:2606-8.
144. Korth-Bradley JM, Parks V, Buckwalter ME. Lack of a clinically relevant interaction between etanercept (E) and warfarin (W). American College of Clinical Pharmacy Sprin Practice and Research Forum 2002; Apr 7-10; Savannah (GA).
145. Patat AA, Parks V, Simcoe DK. Lack of clinically relevant interaction between etanercept (E) and digoxin (D). Clin Pharmacol Ther 2002;71:P64.
146. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002;29:1156-65.
147. Malone DC, Ortmeier BG. Cost efficacy of etanercept versus infliximab plus methotrexate in rheumatoid arthritis based on radiographic data. Ann Rheum Dis 2002;61(Suppl 1):338.
148. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000;43:2316-27.
149. Malone DC. Cost-effectiveness analysis of etanercept monotherapy versus infliximab plus methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 2001;44(Suppl 9):S322.
150. Malone DC, Ortmeier BG. Cost efficacy of etanercept versus infliximab plus methotrexate in the treatment of DMARD-resistant rheumatoid arthritis. Ann Rheum Dis 2002;61 (Suppl 1):340.
151. Nuijten MJC, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost-study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001;19:1051-64.
152. Yazdani C, McLaughlin T, Cummins G. Comparison of rheumatoid arthritis care cost in patients starting therapy with leflunomide versus etanercept. Am J Mana Care 2001;7 (Suppl 13):S419-26.
153. Feldman SR, Garton R, Averett W, Balkrishnan R. Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother 2003;4:1525-33.